Comparative assessment of the absorption of a generic formulation of paracetamol / ibuprofen / doxylamine tablet against the innovator paracetamol / codeine phosphate hemihydrate / doxylamine succinate tablets and paracetamol / ibuprofen tablet conducted under fasting conditions in healthy male and female volunteers

Single dose, three-treatment, three-period, six-sequence, crossover, bioequivalence design whereby each participant receives the test formulation of 1 x 500 mg paracetamol, 200 mg ibuprofen and 5.1 mg doxylamine succinate immediate release tablet on one occasion and the innovator formulations of 1 x 500 mg paracetamol, 10 mg codeine phosphate hemihydrate and 5.1 mg doxylamine succinate immediate release tablet on one occasion and 1 x 500 mg paracetamol and 200 mg ibuprofen immediate release tablet on one occasion with each dose seperated by a one week washout period. The intervention for this trial is the test formulation of 500 mg paracetamol, 200 mg ibuprofen and 5.1 mg doxylamine succinate. No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose). Participants are required not to eat for 10 hours prior to dosing. Subjects are required to fast for approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance and will be monitored for 24 hours. Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing. Pre and post study laboratory tests will be completed to assess the health of participants. Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.